Last reviewed · How we verify

NCT04753424

Semitendinosus Graft as Meniscal Transplant

Status unknown Last updated 23 June 2022
What this trial tests

trial testing Surgical technique in Patient Satisfaction in 10 participants. Status unknown.

Timeline
1 January 2018
Primary endpoint
1 January 2024
1 January 2026

Quick facts

Lead sponsorKarolinska Institutet
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment10
Start date1 January 2018
Primary completion1 January 2024
Estimated completion1 January 2026
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Karolinska Institutet

Who can join

Adults 20 to 50, any sex, with Patient Satisfaction or Graft Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Removal of meniscal tissue is described to result in poor knee function and a significant risk for future development of osteoarthritis. Different implants have been suggested to substitute a removed meniscus. Meniscal allograft transplantation is not widely available due to costs and availability. The semitendinosus tendon is a known graft with biological properties with potential to remodel and revascularize in an intraarticular environment such as anterior cruciate ligament reconstruction. The objective for this study was to investigate whether the semitendinosus tendon graft could function as a meniscal transplant.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Patient Satisfaction

Currently open trials in the same condition.

Other Karolinska Institutet trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04753424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing